Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A
Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes
While this can feel like the medication is failing, it is actually a normal part of how the drug is processed
However, understanding your baseline receptor sensitivity and metabolic risk variants can support a more informed, personalized discussion with your provider about which starting approach makes sense for you
Yes, you'll likely experience residual appetite suppression for 24 weeks after your final injection as the drug gradually leaves your system
Treatment of pituitary-dependent cushings disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial